Peptides for the treatment of neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-10040836-B2
Application number	US-201715404378-A
Country	US
Kind code	B2
Filing date	Jan 12, 2017
Priority date	Oct 9, 2012
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X1X2X3X4 X5, wherein X1 is a hydrophobic amino acid or threonine, X2 is a hydrophobic amino acid, X3 is a hydrophobic amino acid, X4 is an acidic amino acid and X5 is selected from the group consisting of glycine, serine and alanine, the peptide capable of specifically inhibiting the activity of caspase 6.

First claim

What is claimed is:

1. A method of treating Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence as set forth in SEQ ID NO: 2, wherein the peptide is capable of specifically inhibiting the activity of caspase 6, thereby treating the Alzheimer's disease.

2. The method of claim 1 , wherein said Htt amino acid sequence is attached to a cell penetrating agent.

3. The method of claim 2 , wherein said cell penetrating agent is a cell penetrating peptide agent.

4. The method of claim 3 , wherein said cell penetrating peptide agent is attached to said Htt amino acid sequence via a linking amino acid sequence.

5. The method of claim 4 , wherein said linking amino acid sequence comprises a disulfide bridge.

6. The method of claim 4 , wherein said linking amino acid sequence is attached to the N terminus of said Htt amino acid sequence.

7. The method of claim 5 , wherein said linking amino acid sequence comprises the sequence SSE.

8. The method of claim 4 , wherein said isolated peptide which comprises said cell penetrating peptide agent and said Htt amino acid sequence is no longer than 25 amino acids.

9. The method of claim 1 , wherein the Htt amino acid sequence inhibits the activity of caspase 6 to a greater extent than it inhibits the activity of caspase 3.

Assignees

• Univ Ramot

Inventors

• Offen Daniel
• Aharony Israel

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K14/4703

  Inhibitors; Suppressors · CPC title

• C07K14/47 Primary

  from mammals · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/10

  containing a tag for extracellular membrane crossing, e.g. TAT or VP22 · CPC title